Introduction
============

Pheochromocytomas are catecholamine-secreting tumors of the chromaffin cells of the adrenal medulla. Extra-adrenal abdominal paragangliomas (here referred to as abdominal paraganglioma or paraganglioma) are related to neuroendocrine tumors in chromaffin cells distributed along the sympathetic ganglia throughout the abdomen. There is an increasing appreciation for the hereditary background of these tumors; indeed, known predisposing gene variations are present in more than 25% of pheochromocytoma and paraganglioma patients ([@bib25]). Four syndromes are closely associated with pheochromocytomas and paragangliomas: MEN2, VHL, neurofibromatosis type 1, and familial paraganglioma syndrome types 1, 3, and 4, which are caused by constitutional mutations in the *RET*, *VHL*, *NF1*, and *SDHD*, *SDHC*, and *SDHB* genes respectively ([@bib13]). Recently, constitutional mutations of *SDHAF2* (*SDH5*) and *SDHA* were also identified in paraganglioma and of *TMEM127* and *MAX* in pheochromocytoma ([@bib16], [@bib5], [@bib27], [@bib36], [@bib10]).

Others and we have previously shown that promoter hypermethylation in tumor suppressor genes (TSGs) is a prominent feature of pheochromocytoma and paraganglioma ([@bib6], [@bib21], [@bib14], [@bib15], [@bib18], [@bib22], [@bib29]). P16 (CDKN2A) and its novel transcript variant P16G are important tumor suppressors that act through the retinoblastoma pathway to regulate the cell cycle ([@bib20]). Knocking out the mouse equivalent of the INK4A locus, Ink4a/Arf, causes a substantial increase in the severity of the disease phenotype in pheochromocytoma-prone mice ([@bib37]). While this region is rarely lost in human pheochromocytomas and paragangliomas, we found that hypermethylation of the residing *P16* gene is strongly associated with malignancy -- 4/5 cases with *P16* hypermethylation were classified as malignant, while only 1/44 tumors without evidence of malignancy harbored *P16* hypermethylation ([@bib18]). We further found concerted hypermethylation in the promoters of the *CDH1*, *DCR2* (*TNFRSF10D*), *p16*^*INK4A*^ (*CDKN2A*), *RASSF1A*, and *RARB* genes in the same panel of 55 pheochromocytomas and paragangliomas ([@bib15]). Coordinated hypermethylation of multiple TSGs was observed in agreement with a CpG island methylator phenotype (CIMP) originally described for colon cancer ([@bib34]). Interestingly, CIMP was associated with malignancy (4/5 cases with CIMP had developed metastases) and with *SDHB* mutation (*SDHB* mutation was detected in 4/5 cases with CIMP, [@bib15] and [@bib18]).

In this study, we aimed to evaluate the possibility that predisposing mutation and TSG hypermethylation are associated events and to substantiate the evidence that TSG hypermethylation is indicative of malignant behavior. We have therefore characterized TSG promoter hypermethylation in relation to global CpG methylation, analogized by assessing methylation in the *LINE1* (*L1RE1*) retrotransposon element, and in relation to disease predisposition in an extended tumor panel of pheochromocytomas and paragangliomas. Notably and as our previous findings indicated a presence of CIMP in strong association with malignant paragangliomas with *SDHB* mutation ([@bib15], [@bib18]), the present panel included additional cases with known mutation in predisposing genes and/or associated syndromes, paragangliomas, and metastatic disease. Furthermore, comparisons were made with non-tumorous material with regard to genetic and epigenetic events in a subset of cases. Our aims were to i) verify the occurrence of TSG hypermethylation in an independent tumor series; ii) assess the temporal relation of methylation to tumor development; iii) determine the chronological relation to genetic alterations; iv) evaluate the relation to mutations in predisposing genes; and v) assess associations to metastatic disease.

Materials and methods
=====================

Patients and clinical samples
-----------------------------

All samples were collected with informed consent and ethical approval from patients surgically treated for pheochromocytoma or abdominal paraganglioma at Sahlgrenska University Hospital, Göteborg or Karolinska University Hospital, Stockholm, Sweden ([Table 1](#tbl1){ref-type="table"}). Fresh frozen tumor samples and matching non-tumor tissues were obtained from the respective endocrine Biobanks and matching leukocytes from peripheral venous samples. In this study, tumors were classified according to the World Health Organization criteria ([@bib11], [@bib33]) whereby only cases with metastases were regarded as malignant.

Tumor series A ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}) constituted of 38 primary tumors and two metastases ([@bib17], [@bib35], [@bib23]) was analyzed for promoter methylation and *SDHB/D* mutation in this study ([Table 2](#tbl2){ref-type="table"}). For Series B ([Table 1](#tbl1){ref-type="table"}), clinical/genetic details and methylation status for tumor samples have been previously published ([@bib12], [@bib15], [@bib18], [@bib30]). In this study, mutation screenings and methylation quantifications in Series B were carried out in matching normal samples from a subset of cases ([Supplementary Table S1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1), see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article). Histopathologically evaluated normal adrenal medullary DNA samples purchased from Clinomics (Watervliet, NY, USA) were used as non-tumor references in methylation analyses.

DNA extractions
---------------

Genomic DNA was extracted from tissue and blood samples applying ChargeSwitch gDNA Mini Tissue Kit (Invitrogen/Life Technologies Corporation). A few of the non-tumor reference cases were extracted using a standard method with proteinase K digestion, phenol--chloroform extraction, and ethanol precipitation. DNA quality and concentrations were assessed using a NanoDrop Spectrophotometer (ND-1000).

Sequencing of the *SDHB* and *SDHD* genes
-----------------------------------------

The coding exons and exon--intron junctions of the *SDHB* and *SDHD* genes were sequenced in tumor and normal DNA samples. *SDHB* sequences were amplified by PCR as eight different fragments and *SDHD* in four different reactions under previously described experimental conditions ([@bib2], [@bib3], [@bib7]). Primer sequences and amplification details are given in [Supplementary Table S2](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1), see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article. PCR amplicons were purified by Exozap-IT (USB, GE Healthcare, Pittsburgh, PA, USA) and sequenced at the KIGene facility at KI, Stockholm, Sweden, using the ABI 3730 DNA Analyzer system (Applied Biosystems). Sequences were subsequently analyzed with the CodonCode and SeqScape Software (Applied Biosystems). Detected sequence alterations were verified and re-sequenced by forward and reverse sequencing of the involved exons.

*SDHB* was sequenced in 22 tumors from Series A (AG-1, -2, -6, -9, -10, -13, -14, -16, -18a, -18b, and -20; AS-21, -23, -28, -32, -33, -34, -35, -37, -38, -39, and -40). These included all paragangliomas and all pheochromocytomas previously described as malignant from Series A. Further, *SDHB* was sequenced in eight tumors from Series B (BS-7, -26, -30, -33, -36, -41, -44, and -45), including paragangliomas and malignant pheochromocytomas. In addition, non-tumorous DNA was sequenced in five cases in Series B with previously reported *SDHB* tumor mutations ([@bib18]) to assess whether mutations were constitutional or not. *SDHD* was sequenced in ten tumors (AS-23, -28, -32, -33, -34, -35, -37, -38, -39, and -40) including samples previously described as malignant in Series A and one tumor in Series B (BS-2) that featured CIMP but where no *SDHB* mutation could be detected ([@bib15], [@bib18]).

Mutation status of predisposing genes
-------------------------------------

Cases with a hereditary form of the disease were identified by mutation screening of constitutional DNA or in some cases based on the clinical presentation as reported in [@bib12] and [@bib23]. In addition, cases with *SDHB* mutations were identified by sequencing of tumor DNA and by verification of constitutional mutations in samples from blood or normal tissues. Results from tumor analyses have been published for Series B in [@bib15] and [@bib18].

Pyrosequencing of promoter regions
----------------------------------

Promoter methylation density was quantified in tumor and normal DNA samples for the TSGs *DCR2*, *CDH1*, *NORE1A*, *P16*, *RARB*, and *RASSF1A* and for *LINE1* repeat elements. All assays were performed according to the PyroMark Assay Database, with the exception of *P16* and *LINE1* that were available as analysis kits from Qiagen. Genomic DNA was sodium bisulfite modified with the EZ DNA Methylation Kit (Zymo Research Corporation, Orange, CA, USA). Target regions were amplified by PCR from 25 to 50 ng DNA using 0.2 mM of the forward and reverse primers detailed in [Supplementary Table S2](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1), 0.2 mM dNTPs, 1.6 units of HotStarTaq, 10× PCR buffer (Qiagen), and for *DCR2* 3.0 mM MgCl~2~ (Qiagen). Subsequent pyrosequencing was carried out using sequencing primers and annealing temperatures listed in [Supplementary Table S2](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1) and Biotage/Qiagen PyroMark equipment (Qiagen).

Methylation indices (MetI) were calculated as the mean of all CpGs assayed for a TSG, and in addition, methylation densities at individual CpGs were considered. Cutoffs for hypermethylation were based on previous analyses of normal adrenal medullary samples ([@bib15], [@bib18], [@bib38]). Hence, cutoffs for hypermethylation were set at \>10% for *CDH1*, *NORE1A*, *P16*, and *RARB* and at \>30% for *DCR2* and *RASSF1A*, the elevated cutoffs being based on observations of higher levels of intrinsic methylation in normal samples for the latter two.

Statistical analyses
--------------------

To allow comparison between samples in relation to various parameters, *Z*-scores were calculated for each sample with reference to each TSG, mean of all TSGs, and *LINE1* in the following way: (mean CpG methylation density for each sample -- mean methylation density for that promoter in the tumor panel)/[s.d]{.smallcaps}. of that methylation density. This negated large differences in mean MetIs between different genes and allowed direct comparison of gene methylation levels, which are expressed as [s.d]{.smallcaps}.s from the mean for the particular gene. STATISTICA 10.0 Software (Statsoft, Inc., Tulsa, OK, USA) was used for all statistical calculations ([Supplementary Table S3](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1), see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article). *Z*-scores were compared for cases with different clinical and genetic features -- summarized in [Table 3](#tbl3){ref-type="table"} -- including age, tumor type, predisposing mutation/syndrome, metastasis, outcome, and relation to CIMP. Mann--Whitney *U* test and Kruskal--Wallis one-way ANOVA test were used to compare groups of continuous data; Fisher\'s exact test was used for comparisons of categorical data, and Spearman\'s rank order correlation was used to assess correlations between continuous data sets. Survival curves for hypermethylated and unmethylated cases in Series A+B were compared by log-rank test for *P16* and *RASSF1A*, and results were illustrated graphically by Kaplan--Meier plots. *P* values \<0.05 were considered as statistically significant. One of the metastases from Series A (AG-18b) was also represented by its primary tumor and was therefore excluded from the statistical calculations.

Results
=======

Promoter hypermethylation in *DCR2*, *CDH1*, *NORE1A*, *P16*, *RARB*, and *RASSF1A*
-----------------------------------------------------------------------------------

Thirty-eight primary tumors and two metastases in Series A were assayed for promoter hypermethylation in multiple CpGs of *DCR2*, *CDH1*, *NORE1A*, *P16*, *RARB*, and *RASSF1A* by pyrosequencing. Three primary tumors fulfilled the criteria of CIMP phenotype, i.e. exhibited increased MetI for three or more genes (AG-9, -14, and -20; [Table 2](#tbl2){ref-type="table"}). Hypermethylation with MetI above cutoff was observed for all genes except *NORE1A*, and in addition, some tumors exhibited increased methylation at ≥1 CpG without raising the MetI above cutoff ([Table 2](#tbl2){ref-type="table"}). Increased MetI was identified in three primary tumors for *DCR2*, three tumors for *CDH1*, five tumors for *P16*, one tumor for *RARB*, and five tumors for *RASSF1A*. In addition, hypermethylation at single CpG(s) was observed for *DCR2* (in four additional primary tumors), *CDH1* (seven tumors), *NORE1A* (five tumors), *P16* (four tumors), and *RASSF1A* (six tumors). In the two metastases, hypermethylation was not observed in regard to MetI, although hypermethylation above cutoff was observed at single CpGs in several of the genes (AG-18b and AS-21; [Table 2](#tbl2){ref-type="table"}).

For all promoters, the distribution of methylation densities was relatively even without obvious involvement of single CpGs ([Fig. 1](#fig1){ref-type="fig"}). However, the methylation levels varied largely between genes; *DCR2*, *P16*, and *RASSF1A* showed the highest levels, while methylation was less pronounced for *CDH1*, *NORE1A*, and *RARB* ([Fig. 1](#fig1){ref-type="fig"}). For *DCR2* and *RASSF1A*, the higher densities also coincided with somewhat higher levels of methylation in normal references, while this was not the case for *P16*.

Association of TSG hypermethylation with clinical and genetic features
----------------------------------------------------------------------

Methylation densities in cases with different clinical and genetic features from Series A and B were compared using *Z*-scores calculated for the mean of all TSGs as well as for each individual TSG. Importantly, higher mean *Z*-score was significantly associated with mutation (*SDHB*), tumor type (paraganglioma), metastatic disease, death of disease, and CIMP ([Fig. 2](#fig2){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}). High *Z*-scores for individual TSG promoters were also significantly associated with different clinical and genetic features including *SDHB* mutation (all save *NORE1A*), paraganglioma tumor type (all), metastasis (all), and death of disease (all except *RARB*, with *RASSF1A* being highly significant) ([Table 3](#tbl3){ref-type="table"}). [Supplementary Table S3](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1) details the outcome of the statistical tests performed.

TSG hypermethylation in relation to *SDHB* mutation
---------------------------------------------------

The heat map in [Fig. 3](#fig3){ref-type="fig"} illustrates the patterns of TSG hypermethylation in cases with different forms of heritable disease. Altogether, 32 primary tumors and two metastases from the combined Series A+B were from patients with a hereditary form of the disease based on (familial) syndromic presentation and/or identified germ-line mutations. The 11 *SDHB*-positive tumors from ten cases exhibited promoter hypermethylation for two or more of the investigated genes concerning MetI or the maximum for at least one individual CpG. Specifically, increased methylation was observed in 11/11 tumors for *P16*, 9/11 for *DCR2*, 7/11 for *RASSF1A*, 6/11 for *CDH1*, 5/11 for *RARB*, and 4/11 for *NORE1A* ([Fig. 3](#fig3){ref-type="fig"}). For *P16*, *DCR2*, and *RASSF1A*, the hypermethylation was, with few exceptions, pronounced, with MetI above cutoff. By contrast, tumors from patients associated with *RET*/MEN2 (*n*=12), NF1 (*n*=7), or *VHL*/VHL (*n*=3) exhibited increased methylation for individual CpGs in nine instances only, and MetI did not exceed background level. Taken together, the combined observations in Series A+B strongly support an association between *SDHB* mutation and TSG hypermethylation, with *P16* being the most frequently involved.

Order of genetic events and TSG hypermethylation in tumor development
---------------------------------------------------------------------

To evaluate the relationship between occurrence of genetic and epigenetic events in the tumor development, matched samples of normal and tumor tissues were compared in five cases from Series B ([Fig. 4](#fig4){ref-type="fig"}; [Supplementary Table S1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1)). All five primary tumors and two metastases from the five patients have previously been reported to carry increased promoter MetI in two to five of the investigated genes *DCR2*, *CDH1*, *NORE1A*, *P16*, *RARB*, or *RASSF1A* ([@bib14], [@bib15], [@bib18]). In four of the five cases, three or more TSG promoters showed increased MetI in agreement with a CIMP phenotype. By contrast, pyrosequencing of the same promoters in constitutional DNA revealed only very low levels of CpG methylation in all five cases ([Supplementary Table S1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1)).

Four of the five cases carried a constitutional inactivating mutation of the *SDHB* gene that was present in normal, tumor, and metastasis analyzed. In mutated cases, double peaks of mutated and wild-type sequences were observed in constitutional DNA, in agreement with heterozygous state of the mutations ([Supplementary Figure S1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1), see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article). The occurrence of genetic and epigenetic events from constitutional tissue to primary tumor and metastasis is outlined in [Fig. 4](#fig4){ref-type="fig"} for the five cases. Hence, *SDHB* mutations were present constitutionally, while TSG hypermethylation and CIMP were acquired events first observed in primary tumors together with loss of chromosomal region 1p encompassing the *SDHB* locus, and subsequently retained to metastatic tissue.

Global methylation of *LINE1* repeat elements
---------------------------------------------

MetI levels for *LINE1* repeat elements varied from 46 to 80% in the 39 primary tumors in Series A, and the values at the individual CpGs ranged from 37 to 83% ([Table 2](#tbl2){ref-type="table"}). The two metastases exhibited MetI of 71 and 76% (range 70--79%). These results overlap with those in normal adrenal references, where MetI at 68--71% and individual CpGs methylation within the range 65--76% are observed. *LINE1* *Z*-scores differed significantly between the genders (higher mean value in males).

Discussion
==========

We here report significantly higher mean TSG methylation levels in paragangliomas, metastasizing tumors, *SDHB*-mutated tumors, and cases with poor survival ([Fig. 2](#fig2){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}). Taken together, these findings in the novel tumor Series A powerfully substantiate similar observations from Series B ([@bib15]).

We have previously defined CIMP as mean CpG hypermethylation above the normal range cutoff in three or more TSG promoters. To herein provide a more detailed assessment of the epigenetic events in these tumors, we have also considered methylation at individual CpGs ([Fig. 1](#fig1){ref-type="fig"}; [Table 2](#tbl2){ref-type="table"}). *Z*-scores denoting individual TSG methylation levels, as well as mean *Z*-scores for all TSGs in each case, were compared with clinical and genetic features ([Table 3](#tbl3){ref-type="table"}).

Indeed, individual TSG hypermethylation was salient in paragangliomas, being especially prominent in tumors classified as malignant. In the combined Series A+B, 7/11 metastasized paragangliomas exhibited MetI above cutoff in two or more of the assessed TSG promoters ([Fig. 5](#fig5){ref-type="fig"}). Further, 4/12 paragangliomas without metastases carried *SDHB* mutations -- strongly linked to malignant behavior and metastatic potential ([@bib4]) -- three of which also exhibited MetI above cutoff for two or more TSGs ([Fig. 5](#fig5){ref-type="fig"}). In contrast, TSG hypermethylation proved infrequent in pheochromocytomas; 5/54 cases featured MetI above cutoff in a single TSG each ([Fig. 5](#fig5){ref-type="fig"}). The most frequently hypermethylated genes were *DCR2* (eight tumors), *P16* (11 tumors (AG-6 exhibited elevated MetI, but was nonetheless. Five percentage points too low to reach cutoff)), and *RASSF1A* (nine tumors), indicating that epigenetic modifications of these genes is an important facet of malignancy in paragangliomas.

We found a very strong association between *SDHB* mutation and hypermethylation of several TSGs in the novel Series A ([Fig. 2](#fig2){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}), in agreement with our previous reports of an association to *P16* hypermethylation ([@bib18]). The *Z*-score box plots in [Fig. 2](#fig2){ref-type="fig"}, grouped by syndrome/mutation, further highlight the over-representation of TSG CpG methylation coinciding with *SDHB* mutation compared with other genetic variants. *P16* hypermethylation was most frequently seen with and was unequivocally associated with *SDHB* mutation ([Fig. 2](#fig2){ref-type="fig"}; [Table 2](#tbl2){ref-type="table"}). Furthermore, for the paraganglioma AG-6 with *SDHB* mutation, the MetI for *P16* was elevated and close to the nominal 10% cutoff value, and hypermethylation above cutoff was observed for individual CpGs. Similarly, the *SDHB*-mutated paraganglioma lymph node metastasis AS-21 exhibited a MetI of 8% (range 4--12%) for *P16*. This observation is perhaps indicative of a developing phenotype or a result of tumor heterogeneity. By contrast, MetI levels for *P16* were very low (1 or 2%) in tumors without detectable *SDHB* mutation. [Figure 3](#fig3){ref-type="fig"} further illustrates that in the combined Series A+B, concerted epigenetic events occur in relation to *SDHB* mutation but are not observed in association with other predisposing syndromes. Survival analyses of combined Series A+B demonstrated significantly shorter survival in patients with primary tumors that displayed *P16* MetI \>10% compared with those with MetI below cutoff ([Fig. 6](#fig6){ref-type="fig"}).

In Series A as well as in combined Series A+B, hypermethylation of TSGs was found in association with paraganglioma tumor type, development of metastases, and mutation of the predisposing gene *SDHB*. While metastasis and *SDHB* mutations are known to be correlated, the question arises whether hypermethylation also occurs in *SDHB* wild-type metastatic tumors. *SDHB* mutations were not identified in 6 of the 14 metastatic tumors in this study. Among these, only two paragangliomas had hypermethylation. Significant methylation in *RASSF1A* alone was detected when analyzing TSG methylation in all metastatic tumors without apparent *SDHB* involvement (*P*≥0.02). Hence, increased TSG methylation does not appear to be frequently involved in sporadic, malignant cases or in conjunction with other predisposing mutations. However, it is presently unknown whether metastatic tumors with mutations other than *SDHB* harbor TSG methylation. We see no such involvement in benign tumors with known mutations other than *SDHB* ([Fig. 3](#fig3){ref-type="fig"}).

*SDHB* mutations are known to be frequently associated with malignant forms of paraganglioma ([@bib28]), raising questions about causes and consequences in relation to these abnormalities and their clinical effects. In four cases with constitutional *SDHB* mutations in Series B, TSG hypermethylation was absent in constitutional DNA -- indicating that the TSG hypermethylation is tumor-specific -- and first observed in primary tumors in conjunction with loss of 1p encompassing the *SDHB* gene locus ([Fig. 4](#fig4){ref-type="fig"}). Furthermore, acquired TSG hypermethylation was observed in four malignant primary paragangliomas before the development of metastasis and one case where metastasis had not developed before surgery (BS-10; [Fig. 4](#fig4){ref-type="fig"}). Importantly, these findings implicate that TSG hypermethylation is not a secondary consequence of a malignant tumor state. Furthermore, they would imply that heterozygous *SDHB* inactivating mutations do not confer detectable TSG hypermethylation at the constitutional level, at least not for the tissues/genes assessed here. However, it is a theoretical possibility that heterozygous *SDHB* inactivation could lead to TSG hypermethylation in cancer progenitor cells of the target tissue and subsequently be selected for at tumor transformation.

The data presented here strongly indicate that *SDHB* inactivation and TSG CpG hypermethylation are associated; an attractive possibility being that *SDHB* inactivation in fact causes TSG hypermethylation. To our knowledge, this would represent the first instance where a known hereditary cancer syndrome (familial paraganglioma syndrome type 4) is linked to an epigenetic phenotype. The link between SDH loss and epigenetic remodeling represented by histone modifications was recently shown ([@bib32], [@bib9]). Importantly, the breakdown of the mitochondrial respiratory chain by loss of SDH function leads to accumulation of succinate, which causes inhibition of α-ketoglutarate-dependent enzymes (that normally produce succinate as a byproduct; [@bib19], [@bib31]). Among them are the jumonji-domain histone demethylases ([@bib32]) that regulate histone H3 and H4 lysine and arginine methylation ([@bib1], [@bib9]). This would overture a general inhibition of histone demethylase activity ([@bib9]), likely affecting chromatin on a global level. It is plausible that these histone modifications and the epigenetic perturbances observed in the current project have a joint causality. However, we observe a very specific pattern of promoter CpG methylation in our tumor panel, while global methylation patterns analogized by *LINE1* remain heterogeneous regardless of *SDHB* status. This specific methylative inactivation of apoptotic and antiproliferative genes might instead mirror a physiological attempt to counter the state of pseudo-hypoxia, induced by SDH dysfunction and described in [@bib26] and [@bib8]. Indeed, recent immunohistochemical studies have shown that tumors from patients with *SDHB*, *SDHC*, and *SDHD* mutations lack SDHB immunoreactivity and that SDH activity is abolished in *SDHB*- and *SDHD*-mutated cases but not in connection with *SDHC* ([@bib24]). These observations contrast those in tumors from patients with predisposing mutations in other genes. Based on the results, the authors recommended that screening for SDH gene mutations should be carried out in cases with negative SDHB immunohistochemistry ([@bib24]). Another implication from these interesting findings is that the increased risk of malignancy associated with SDHB would not be a direct result of SDHB protein loss but relate to other molecular abnormalities perhaps occurring at the transcriptional level.

Recognition of constitutional mutation carriers among pheochromocytoma and paraganglioma patients is of clinical importance but in principle requires extensive mutation screenings in a large group of patients -- as several genes are involved, and hereditary predisposition is often present in spite of a negative family history. The findings presented here suggest that methylation quantification for *P16* promoter CpGs could be a valuable clinical tool in the assessment of paragangliomas and that cases with *P16* hypermethylation should be genetically screened for *SDHB* mutations.

In summary, our results associated mutation of the *SDHB* gene to alterations in TSG methylation in paragangliomas. We here propose that epigenetic inactivation of TSGs is an important component in familial paraganglioma syndrome and suggest inquiries into the use of demethylating agents as a means to combat malignant paragangliomas. Future analyses should also encompass the assessment of gene-specific methylation in *SDHB*-deficient paragangliomas using methylation arrays. We further propose the use of *P16* methylation assessment as an additive tool in identification of patients for *SDHB* mutation screenings.

Supplementary data {#supp1}
==================

This is linked to the online version of the paper at <http://dx.doi.org/10.1530/ERC-12-0267>.

Dedicated to the memory of Håkan Ahlman, 1947--2012. The authors wish to thank Stefano Caramuta for expert assistance with survival analyses.

Declaration of interest
=======================

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
=======

The study was financially supported by grants from Swedish Cancer Society, Swedish Research Council, Göran Gustafsson Foundation for Research in Natural Sciences and Medicine, Gustav V Jubilee Foundation, Karolinska Institutet, and Stockholm County Council.

![Methylation densities of promoter regions for individual tumor suppressor genes measured by pyrosequencing for pheochromocytomas and paragangliomas in Series A. Scatterplots illustrate methylation levels (%) at individual CpG sites assayed in each tumor sample. Cutoff levels for hypermethylation determined from normal adrenal medulla are indicated by arrows for *DCR2* (\>30%), *CDH1* (\>10%), *NORE1A* (\>10%), *P16* (\>10%), *RARB* (\>10%), and *RASSF1A* (\>30%).](ERC120267f01){#fig1}

![Boxplots illustrate the significant associations in Series A and A+B between increased mean *Z*-scores and metastatic disease and *SDHB* mutation, as well as between high *P16* *Z*-score and *SDHB* mutation.](ERC120267f02){#fig2}

![Association between *SDHB* mutation, tumor suppressor gene hypermethylation, and metastasis. Methylation densities are illustrated for individual tumors in Series A+B from patients with predisposing mutations and/or syndromic disease related to *SDHB*, *RET*/MEN2, NF1, or *VHL*/VHL. Tumors with MetI levels above cutoff are indicated by dark blue boxes, above cutoff for one or more CpG sites by light blue boxes, and below cutoff levels by green boxes. Cutoff levels for individual genes are \>30% for *DCR2* and *RASSF1A* and \>10% for *CDH1*, *NORE1A*, *P16*, and *RARB*. Cases with metastasis are indicated to the right. \*Metastasis from the tumor in the row above.](ERC120267f03){#fig3}

![Schematic illustrations of genetic and epigenetic events detected in normal tissue, primary tumors, and metastasis from tumor Series B. Genetic events concerning constitutional *SDHB* mutations and somatic loss of 1p in primary tumors are illustrated above the flow charts. Detection of promoter hypermethylation -- reflected in increased MetI -- and methylation above the cutoff for one or more CpG only (in parenthesis) are indicated below for the TSG promoter concerned (see [Supplementary Table S1](http://erc.endocrinology-journals.org/cgi/content/full/ERC-12-0267/DC1) for exact values). Samples assayed are shown in bold and by solid lines, while metastases not assayed are indicated by dotted lines.](ERC120267f04){#fig4}

![Comparison of promoter hypermethylation at individual tumor suppressor gene promoters in paraganglioma and pheochromocytoma with and without metastasis from tumor combined Series A+B. Methylation levels are indicated as dark blue boxes for MetI above cutoff, light blue boxes refer to one or more CpG sites above cutoff, and green boxes denote promoters without detected hypermethylation. Cutoff levels for individual genes were applied at \>30% (*DCR2*and *RASSF1A*) or \>10% (*CDH1*, *NORE1A*, *P16*, and *RARB*). \*AG-6 displays elevated *P16* MetI just under cutoff.](ERC120267f05){#fig5}

![Kaplan--Meyer plots illustrating the significant association between short disease-related (A) and overall (B) survival and hypermethylation of *P16* based on data from combined Series A+B.](ERC120267f06){#fig6}

###### 

Clinical and genetic details for pheochromocytoma/paraganglioma cases

  **Parameter**           **This study**            
  ----------------------- ---------------- -------- --------
  No of cases                                       
   Patients               39               54       93
   Tumors                 40               56       96
  Samples studied                                   
   Blood/normal tissues   --               5        
   Primary tumors         38               54       92
   Metastases             2                2        4
  Gender                                            
   Female                 20               31       51
   Male                   18               23       41
  Age at diagnosis                                  
   Range (years)          17--81           13--77   13--81
  Syndrome/mutation                                 
   *SDHB*                 6                4        10
   MEN2/*RET*             9                3        12
   NF1                    5                2        7
   VHL/*VHL*              2                1        3
  Diagnosis                                         
   Pheochromocytoma       27               43       70
   Paraganglioma          12               11       23
   Metastasized           7                7        14
   Without metastasis     32               47       79
   Bilateral/multiple     7                6        13
  Survival                                          
   DOD                    4                2        6
   DOC                    7                6        13
   A                      27               45       72

DOD, dead of disease; DOC, dead of other cause; A, alive, no reported disease.

Data for tumors from [@bib15] and [@bib18].

###### 

Results from methylation quantifications of promoter regions in tumor Series A

                                                           ***DCR2*** (% meth)   ***CDH1*** (%)   ***NORE1A*** (%)   ***P16*** (%)   ***RARB*** (%)   ***RASSF1A*** (%)   ***LINE-1*** (%)                                                                
  ------------------ -------- ----- -------- ------ ------ --------------------- ---------------- ------------------ --------------- ---------------- ------------------- ------------------ ------------ -------- ----------- -------- ------------ ---- --------
  AG-1               Pheo     No    MEN2     --     −0.2   4                     1--8             2                  1--4            2                1--6                1                  1--2         3        2--4        17       6--**36**    46   37--54
  AG-2               Paraga   Met   *SDHB*   --     0.5    15                    11--26           **11**             4--**18**       3                1--7                **10**             8--**13**    4        3--7        7        7--8         75   74--77
  AG-3               Pheo     No    *RET*    --     −0.4   3                     1--7             3                  1--**15**       2                1--6                1                  1--1         3        2--4        2        1--3         68   65--73
  AG-4               Pheo     No    NF1      --     0.1    21                    6--**33**        4                  1--6            2                2--5                2                  0--9         3        0--5        10       7--15        75   71--77
  AG-5               Pheo     No    NF1      --     −0.4   4                     2--9             3                  1--6            2                1--6                1                  1--2         --       --          3        2--3         71   66--75
  AG-6               Paraga   No    *SDHB*   --     0.2    12                    6--20            8                  2--**20**       3                1--6                9                  3--**17**    2        1--3        11       5--20        77   75--78
  AG-7               Pheo     No    NF1      --     −0.2   13                    4--22            4                  1--7            2                1--5                1                  1--2         2        1--3        7        3--11        74   70--76
  AG-8               Pheo     No    *RET*    --     −0.5   2                     1--4             3                  1--5            2                1--5                1                  1--2         2        1--3        2        1--3         76   71--81
  AG-9               Paraga   Met   *SDHB*   CIMP   2.8    **49**                22--**64**       4                  1--7            6                3--**11**           **50**             **40--57**   **21**   4--**37**   **42**   **39--47**   68   64--74
  AG-10              Pheo     No    --       --     0.1    6                     1--15            4                  1--**20**       2                1--5                1                  0--2         2        0--3        **35**   30--**42**   72   70--76
  AG-11              Pheo     No    *VHL*    --     −0.3   4                     1--5             4                  1--7            2                1--4                1                  1--2         3        2--3        2        1--3         80   76--83
  AG-12              Pheo     No    *VHL*    --     −0.3   6                     1--12            5                  1--10           2                1--6                1                  1--1         2        1--3        1        1--1         77   75--78
  AG-13              Paraga   No    --       --     0.5    25                    6--**43**        5                  2--8            2                1--5                **29**             **15--49**   2        0--4        12       8--16        78   75--81
  AG-14              Paraga   Met   *SDHB*   CIMP   2.8    **50**                **34--58**       **24**             5--**53**       8                3--**27**           **40**             **32--47**   2        2--4        28       25--**33**   79   78--79
  AG-15              Pheo     No    NF1      --     −0.3   3                     1--5             4                  2--5            2                1--4                1                  1--2         --       --          13       4--**33**    73   68--76
  AG-16              Paraga   No    --       --     −0.4   3                     1--4             3                  2--5            2                1--6                1                  1--1         --       --          8        4--15        76   72--78
  AG-17              Pheo     No    *RET*    --     0.0    7                     2--13            5                  2--8            4                1--**11**           1                  1--2         4        3--5        3        2--4         77   75--79
  AG-18a             Paraga   Met   --       --     0.6    13                    7--18            5                  2--8            2                1--6                **21**             **18--25**   --       --          30       27--**33**   72   70--73
  AG-18b             Paraga         --       --     --     16                    3--**34**        4                  2--8            4                2--**11**           1                  1--2         3        2--6        3        2--4         76   73--79
  AG-19              Pheo     No    *RET*    --     −0.3   5                     2--11            2                  1--5            3                1--**11**           4                  1--**14**    2        0--3        2        1--3         70   66--74
  AG-20              Paraga   No    *SDHB*   CIMP   1.3    **45**                17--**69**       4                  1--6            2                1--7                **40**             14--59       3        2--5        **32**   15--**51**   64   61--70
  AS-21              Paraga   Met   *SDHB*   --     0.6    27                    6--**48**        6                  2--8            2                1--6                8                  4--**12**    8        2--**25**   17       8--28        76   70--74
  AS-22              Pheo     No    *RET*    --     −0.4   4                     0--11            3                  0--7            2                0--8                2                  0--6         0        0--0        9        1--30        62   57--66
  AS-23              Pheo     No    --       --     −0.3   2                     0--14            8                  0--**29**       2                0--6                0                  0--1         1        0--4        9        0--21        64   57--70
  AS-24              Pheo     No    NF1      --     −0.6   5                     2--11            5                  3--8            0                0--4                2                  0--4         1        0--4        2        0--4         61   58--63
  AS-25              Pheo     No    MEN2     --     −0.7   2                     0--6             1                  0--5            1                0--3                0                  0--1         0        0--3        8        6--11        51   46--57
  AS-26              Pheo     No    *RET*    --     −0.4   11                    4--17            2                  0--7            1                0--4                2                  1--3         2        0--5        7        1--20        59   57--61
  AS-27              Pheo     No    *RET*    --     −0.5   1                     0--3             6                  0--**45**       1                0--6                0                  0--1         0        0--4        0        0--1         63   58--68
  AS-28              Pheo     No    --       --     −0.3   5                     2--11            6                  3--9            1                0--4                2                  0--4         3        0--9        2        0--4         63   59--65
  AS-29              Pheo     No    --       --     −0.3   10                    0--**47**        2                  0--4            2                0--5                2                  1--4         2        0--8        11       4--**34**    59   53--63
  AS-30              Pheo     No    --       --     −0.5   1                     0--4             --                 --              1                0--5                0                  0--1         0        0--4        12       4--24        61   58--65
  AS-31              Pheo     No    --       --     0.2    16                    3--**58**        6                  0--**23**       1                0--5                1                  0--1         0        0--4        **38**   22--**50**   56   53--58
  AS-32              Pheo     No    --       --     −0.2   2                     0--5             **14**             4--**34**       1                0--4                1                  0--3         0        0--0        3        3--5         63   58--67
  AS-33              Pheo     No    --       --     −0.5   11                    0--24            3                  0--7            1                0--4                1                  0--1         0        0--4        1        1--2         66   64--67
  AS-34              Pheo     No    --       --     −0.4   19                    5--**35**        3                  0--5            1                0--5                1                  1--2         1        0--3        8        5--11        64   60--67
  AS-35              Pheo     No    --       --     −0.5   1                     0--4             4                  0--**15**       1                0--5                2                  0--8         1        0--6        1        1--1         60   56--63
  AS-36              Pheo     No    --       --     −0.3   9                     0--**32**        2                  0--3            1                0--5                0                  0--1         0        0--0        24       4--**39**    54   47--57
  AS-37              Paraga   No    --       --     −0.4   2                     0--5             3                  0--7            2                0--7                1                  0--5         1        0--5        12       0--**38**    68   65--74
  AS-38              Paraga   Met   --       --     −0.2   3                     1--6             --                 --              3                0--7                1                  0--1         0        0--2        14       6--17        53   49--55
  AS-39              Paraga   No    --       --     −0.3   3                     0--5             7                  3--10           1                0--4                2                  0--3         4        2--6        0        0--1         66   64--67
  Reference values                                                                                                                                                                                                                                        
  Cutoff (%)                                               \>30                  \>30             \>10               \>10            \>10             \>10                \>10               \>10         \>10     \>10        \>30     \>30              

meth, methylation; range, minimum--maximum value detected at an individual. CpG G-18a and G-18b are primary tumor and metastasis from the same patient.

###### 

Correlations between *Z*-scores and clinical/genetic characteristics

  **Promoter**      **Gender**   **Age at surgery**   **Mutation**   **Tumor type**   **Metastatic disease**   **Outcome**   **CIMP**
  ----------------- ------------ -------------------- -------------- ---------------- ------------------------ ------------- ------------
  Series A                                                                                                                   
   Mean *Z*-score   NS           NS                   \<0.007        \<0.0002         \<0.0004                 0.01          \<0.005
   *DCR2*           NS           NS                   \<0.01         0.01             \<0.02                   NS            \<0.005
   *CDH1*           NS           NS                   NS             NS               \<0.04                   NS            NS
   *NORE1A*         NS           NS                   NS             0.002            \<0.006                  0.01          0.01
   *P16*            0.04         NS                   0.005          0.001            \<0.05                   NS            \<0.005
   *RARB*           NS           NS                   0.02           \<0.005          NS                       NS            \<0.05
   *RASSF1A*        NS           NS                   0.005          \<0.008          0.002                    0.009         0.01
   *LINE1*          0.003        \<0.05               NS             NS               NS                       NS            NS
  Series A+B                                                                                                                 
   Mean *Z*-score   NS           NS                   0.0002         \<0.00001        0.0006                   \<0.0009      \<0.000001
   *DCR2*           \<0.002      NS                   0.0003         \<0.0002         0.01                     \<0.02        \<0.000001
   *CDH1*           NS           NS                   \<0.01         0.03             0.04                     0.03          NS
   *NORE1A*         NS           NS                   NS             0.01             0.005                    \<0.04        0.02
   *P16*            NS           NS                   0.0002         0.00002          0.002                    \<0.02        \<0.000001
   *RARB*           NS           NS                   0.003          \<0.008          \<0.05                   NS            \<0.0003
   *RASSF1A*        NS           NS                   0.0002         0.0004           \<0.0004                 \<0.0008      \<0.000001
   *LINE1*          \<0.002      NS                   NS             NS               NS                       NS            NS

NS, not significant.
